All In Biotech

NDA 208090 · Collegium Pharm INC

Xtampza Er

Oxycodone · Oral · Opioid Agonist

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Apr 26, 2016

Approved uses

2

Original approval plus efficacy supplements

Registered trials

646

137 Phase 3, 50 recruiting

FAERS reports

108,968

83,817 serious, 24,820 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF XTAMPZA ER WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF XTAMPZA ER See full prescribing information for complete boxed warning . XTAMPZA ER exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk before prescribing and reassess regularly for these behaviors and conditions. ( 5.1 ) Serious, life-threatening, or fatal respiratory depression may occur especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of XTAMPZA ER are essential. ( 5.2 ) Accidental ingestion of XTAMPZA ER, especially by children, can result in fatal overdose of oxycodone. ( 5.2 ) Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in...

What it is approved for

From the label in effect Dec 30, 2025.

XTAMPZA ER is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. XTAMPZA ER is an opioid agonist indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death,which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including XTAMPZA ER, for use in patients for whom alternative treatment optionsare ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 ) XTAMPZA ER is not indicated as an as-needed (prn) analgesic. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.1) ], reserve opioid analgesics, including XTAMPZA ER, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. XTAMPZA ER is not indicated as an as-needed (prn) analgesic.

Mechanism: Oxycodone is a full opioid agonist and is relatively selective for the mu receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been...

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • XTAMPZA ER · OXYCODONE 18MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • XTAMPZA ER · OXYCODONE 9MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • XTAMPZA ER · OXYCODONE 27MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • XTAMPZA ER · OXYCODONE 13.5MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription
  • XTAMPZA ER · OXYCODONE 36MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Oxycodone" as an intervention, any sponsor and status, largest first.

All 646 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain11,316
  • fatigue9,976
  • drug ineffective9,424
  • nausea8,498
  • off label use7,127
  • diarrhoea6,890
  • death6,704
  • dyspnoea6,514
  • rash6,278
  • arthralgia6,169
  • vomiting6,157
  • headache5,710

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004225
2005342
2006287
200766
2008215
2009918
20101,403
20111,232
20121,680
20133,893
20145,008
20157,649
20167,268
20177,796
20188,859
20199,014
20209,376
20219,074
20229,048
20237,206
20246,827
20256,975
20264,606

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xtampza ER (Oxycodone Myristate)

2024 spending

$233M

Beneficiaries

50,981

371,096 claims

Per beneficiary

$4,565

$11.04 per unit

View as table
YearSpending
2020$161,277,680
2021$240,889,559
2022$259,804,241
2023$250,042,795
2024$232,750,637

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,202 on PubMed

Sponsor: Collegium Pharm INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.